Bioavailability Containment Drugs Marketing 
XTalks
DECEMBER 5, 2022
Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2
Pharmaceutical Technology
AUGUST 22, 2022
Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. They also offer enhanced bioavailability, exact dosing and an extended shelf life. Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 26, 2020
As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.
The Pharma Data
JANUARY 3, 2021
The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. . +46 7686 650 11. 2 Proof of Concept.
The Pharma Data
JANUARY 20, 2021
Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. It also showed that Nefecon was generally well-tolerated.
The Pharma Data
DECEMBER 3, 2020
Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. About Maribavir. Forward-Looking Statements.
The Pharma Data
DECEMBER 8, 2020
The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Forward-Looking Statements.
Expert insights. Personalized for you.
97 
Let's personalize your content